CIRSARC: Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

Sponsor

Institut Bergonié (Other)

Overall Status

Recruiting

CT.gov ID

NCT03805022

Collaborator

Novartis (Industry), Chugai Pharma France (Industry)

351

Enrollment

Locations

Arms

71.6

Anticipated Duration (Months)

35.1

Patients Per Site

0.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objective of this trial is to investigate whether the addition of 3 additional neo-adjuvant cycles of chemotherapy (doxorubicin based chemotherapy) to standard management according to the ISG-STS 10-01 study (3 cycles of neoadjuvant doxorubicin based chemotherapy

surgery +/- radiotherapy) improves the outcome of high-risk CINSARC patients with resectable soft-tissue sarcoma (STS). Primary endpoint is metastatic progression-free survival (M-PFS, after 3 years of follow-up).

Condition or Disease	Intervention/Treatment	Phase
Non-metastatic Soft-tissue Sarcoma Resectable	Drug: Doxorubicin Drug: Ifosfamide or dacarbazine Drug: Doxorubicin Drug: Ifosfamide or dacarbazine Drug: At the discretion of the investigator	Phase 3

Detailed Description

For high-risk CINSARC patients, this is a multicenter randomized two-arm phase III trial, with a ratio 1:1:

Arm A: standard management (3 cycles of neoadjuvant doxorubicin based chemotherapy + surgery +/- radiotherapy)
Arm B: experimental arm (6 cycles of neoadjuvant doxorubicin based chemotherapy + surgery +/- radiotherapy)

For low-risk CINSARC patients, this a multicenter prospective cohort with treatment at the discretion of the investigator.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

351 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

This is a multicenter trial with: An open randomized two-arm phase III trial for high-risk CINSARC patients assessing whether the addition of 3 additional neo-adjuvant cycles of chemotherapy (doxorubicin based chemotherapy) to standard management (3 cycles of neoadjuvant anthracycline based chemotherapy + surgery +/- radiotherapy) improves the outcome of patients a prospective cohort for low-risk CINSARC patients.This is a multicenter trial with:An open randomized two-arm phase III trial for high-risk CINSARC patients assessing whether the addition of 3 additional neo-adjuvant cycles of chemotherapy (doxorubicin based chemotherapy) to standard management (3 cycles of neoadjuvant anthracycline based chemotherapy + surgery +/- radiotherapy) improves the outcome of patients a prospective cohort for low-risk CINSARC patients.

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase III Trial Investigating the Potential Benefit of Intensified Peri-operative Chemotherapy With in High-risk CINSARC Patients With Resectable Soft-tissue SARComas

Actual Study Start Date :

Feb 14, 2019

Anticipated Primary Completion Date :

Feb 1, 2025

Anticipated Study Completion Date :

Feb 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm A Control-Arm phase III high-risk CINSARC: Patients will be treated by doxorubicin (60 or 75mg/m² day or 20- or 25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices of a 21-days cycle for up to 3 cycles in neoadjuvant setting Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting).	Drug: Doxorubicin A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 3 cycles. Drug: Ifosfamide or dacarbazine A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 3 cycles.
Experimental: Arm B Experimental-Arm phase III high-risk CINSARC: Patients will be treated by doxorubicin (60 or 75mg/m² day or 20 or 25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices of a 21-days cycle for up to 6 cycles in neoadjuvant setting Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting).	Drug: Doxorubicin A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 6 cycles. Drug: Ifosfamide or dacarbazine A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 6 cycles.
Experimental: Prospective cohort Patients will be treated at the discretion of the investigator	Drug: At the discretion of the investigator Drug at the discretion of the investigator.

Arm

Intervention/Treatment

Experimental: Arm A

Control-Arm phase III high-risk CINSARC: Patients will be treated by doxorubicin (60 or 75mg/m² day or 20- or 25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices of a 21-days cycle for up to 3 cycles in neoadjuvant setting Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting).

Drug: Doxorubicin

A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.

Drug: Ifosfamide or dacarbazine

A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 3 cycles.

Experimental: Arm B

Experimental-Arm phase III high-risk CINSARC: Patients will be treated by doxorubicin (60 or 75mg/m² day or 20 or 25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices of a 21-days cycle for up to 6 cycles in neoadjuvant setting Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting).

Drug: Doxorubicin

A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.

Drug: Ifosfamide or dacarbazine

A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 6 cycles.

Experimental: Prospective cohort

Patients will be treated at the discretion of the investigator

Drug: At the discretion of the investigator

Drug at the discretion of the investigator.

Outcome Measures

Primary Outcome Measures

Metastasis progression-free survival in High-risk CINSARC patients [3 years]
Metastasis progression-free survival (M-PFS) defined as the time interval between the date of randomization and the date of death or distant progression.

Secondary Outcome Measures

Loco-regional relapse-free survival in High-risk CINSARC patients [3 years]
Loco-regional relapse-free survival (LR-RFS) defined as the time interval between the randomization date and the date of death or loco-regional progression.
Progression-free survival in High-risk CINSARC patients [3 years]
Progression-free survival (PFS) defined as the time interval between the randomization date and the date of death or progression (as per RECIST v1.1).
Overall survival in High-risk CINSARC patients [3 years]
Overall survival (OS) defined as the time interval between the randomization date and the date of death.
Best overall response in High-risk CINSARC patients [Throughout the treatment period, an average of 6 months]
Best overall response under treatment as per RECIST v1.1.
Histological response in High-risk CINSARC patients [An average of 6 months]
Histological response defined as the proportion of recognizable cells on the tumor sample.
Safety profile in High-risk CINSARC patients [Throughout the treatment period, an average of 6 months]
Toxicity graded using the common toxicity criteria from the NCI v5.
Progression-free survival in Low-risk CINSARC patients [3 years]
Progression-free survival defined as the time interval between the randomization date and the date of death or progression (as per RECIST v1.1).
Metastasis progression-free survival in Low-risk CINSARC patients [3 years]
Metastasis progression-free survival defined as the time interval between the inclusion date and the date of death or distant progression.
Loco-regional progression-free survival in Low-risk CINSARC patients [3 years]
Description of the treatment efficacy in terms of 3-years loco-regional progression-free survival defined as the time interval between the randomization date and the date of death or loco-regional progression.
Overall survival in Low-risk CINSARC patients [3 years]
Overall survival defined as the time interval between the inclusion date and the date of death.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria :

Histologically confirmed soft-tissue sarcoma by the RRePS (Réseau de Référence en Pathologie des Sarcomes et des Viscères) network, as recommended by the French NCI,
Grade 2 or 3 according to the FNCLCC grading system,
Available archived tumour sample for research purpose,
Non-metastatic and resectable disease,
No prior treatment for the disease under study,
Age ≥ 18 years,
Life expectancy ≥ 3 months,
Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1,
Patients must have measurable disease (lesion in previously irradiated field can be considered as measurable if progressive at inclusion according to RECIST 1.1) defined as per RECIST v1.1 with at least one lesion that can be measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm or ≥ 15mm in case of adenopathy,
Women of childbearing potential must have a negative serum pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for one year after discontinuation of treatment. Acceptable methods of contraception include intrauterine device (IUD), oral contraceptive, subdermal implant and double barrier. Subjects of childbearing potential are those who have not been surgically sterilized (e.g., vasectomy for males and hysterectomy for females) or have not been free from menses for ≥ 1 year,
Voluntarily signed and dated written informed consents prior to any study specific procedure,
Patients with a social security in compliance with the French law.

Exclusion Criteria :

Soft-tissue sarcoma with the following histological subtypes: well-differentiated liposarcoma, alveolar soft-part sarcoma, dermatofibrosarcoma protuberans, clearcell sarcoma, embryonal and alveolar rhabdomyosarcoma,
Prior or concurrent malignant disease diagnosed or treated in the last 2 years except for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell carcinoma, or in situ transitional bladder cell carcinoma,
Any other contraindication to anthracycline, ifosfamide or dacarbazine chemotherapy,
Participation to a study involving a medical or therapeutic intervention in the last 28 days,
Known infection with HIV, hepatitis B, or hepatitis C,
Females who are pregnant or breast-feeding,
Other medical conditions may interfere with the conduct of the study and, in the judgment of the investigator, would make the patient inappropriate for entry into this study,
Individuals deprived of liberty or placed under legal guardianship,
Unwillingness or inability to comply with the study protocol for any reason.

Additional criteria for randomization :

High-risk CINSARC signature,
No more than two cycle of neo-adjuvant anthracycline-based chemotherapy before randomization.

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Institut Bergonie	Bordeaux	France	33076
2	Centre Georges François Leclerc	Dijon	France	21079
3	CHU Dupuytren	Limoges	France	87042
4	Centre Léon Bérard	Lyon Cedex 08	France	69373
5	Institut Paoli Calmettes	Marseille	France	13273
6	Insitut du Cancer	Montpellier	France	34298
7	Institut de Cancérologie de l'Ouest - Site René Gauducheau	Saint-Herblain	France	44805
8	CHRU Strasbourg	Strasbourg	France	67200
9	Institut Claudius Regaud	Toulouse	France	31052
10	Institut Gustave Roussy	Villejuif	France	94800